Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	neuroligin family protein binding	NRXN3 NRXN2	9.13e-05	5	61	2	GO:0097109
GeneOntologyBiologicalProcess	vesicle tethering involved in exocytosis	EXOC7 EXOC8 EXOC4	1.84e-06	9	59	3	GO:0090522
GeneOntologyBiologicalProcess	postsynaptic specialization assembly	PTK2B NRXN3 NRXN2 DOCK7	7.52e-06	44	59	4	GO:0098698
GeneOntologyBiologicalProcess	postsynaptic specialization organization	PTK2B NRXN3 NRXN2 DOCK7	5.08e-05	71	59	4	GO:0099084
GeneOntologyBiologicalProcess	vesicle tethering	EXOC7 EXOC8 EXOC4	1.04e-04	32	59	3	GO:0099022
GeneOntologyBiologicalProcess	postsynaptic density assembly	PTK2B NRXN3 NRXN2	1.25e-04	34	59	3	GO:0097107
GeneOntologyBiologicalProcess	postsynapse assembly	PTK2B NRXN3 NRXN2 DOCK7	1.46e-04	93	59	4	GO:0099068
GeneOntologyBiologicalProcess	exocytic process	RIMBP2 EXOC7 EXOC8 EXOC4	2.50e-04	107	59	4	GO:0140029
GeneOntologyBiologicalProcess	postsynapse organization	PTK2B NRXN3 NRXN2 UBE3A STAU2 DOCK7	2.67e-04	313	59	6	GO:0099173
GeneOntologyBiologicalProcess	vesicle docking involved in exocytosis	EXOC7 EXOC8 EXOC4	2.71e-04	44	59	3	GO:0006904
GeneOntologyBiologicalProcess	excitatory synapse assembly	PTK2B NRXN3 NRXN2	3.09e-04	46	59	3	GO:1904861
GeneOntologyBiologicalProcess	transposable element silencing	APOBEC3G DNMT3B APOBEC3F	3.09e-04	46	59	3	GO:0010526
GeneOntologyBiologicalProcess	retrotransposition	APOBEC3G DNMT3B APOBEC3F	3.51e-04	48	59	3	GO:0032197
GeneOntologyBiologicalProcess	membrane fission	EXOC7 EXOC8 EXOC4	3.51e-04	48	59	3	GO:0090148
GeneOntologyBiologicalProcess	DNA cytosine deamination	APOBEC3G APOBEC3F	3.57e-04	10	59	2	GO:0070383
GeneOntologyBiologicalProcess	transposition	APOBEC3G DNMT3B APOBEC3F	3.96e-04	50	59	3	GO:0032196
GeneOntologyCellularComponent	exocyst	EXOC7 EXOC8 EXOC4	3.03e-05	21	61	3	GO:0000145
GeneOntologyCellularComponent	apolipoprotein B mRNA editing enzyme complex	APOBEC3G APOBEC3F	8.33e-05	5	61	2	GO:0030895
GeneOntologyCellularComponent	mRNA editing complex	APOBEC3G APOBEC3F	1.74e-04	7	61	2	GO:0045293
GeneOntologyCellularComponent	growth cone membrane	EXOC7 EXOC4	2.98e-04	9	61	2	GO:0032584
GeneOntologyCellularComponent	growth cone	PTK2B DOCK7 EXOC7 EXOC8 EXOC4	7.40e-04	245	61	5	GO:0030426
GeneOntologyCellularComponent	npBAF complex	SMARCC1 SMARCC2	7.45e-04	14	61	2	GO:0071564
GeneOntologyCellularComponent	brahma complex	SMARCC1 SMARCC2	7.45e-04	14	61	2	GO:0035060
GeneOntologyCellularComponent	site of polarized growth	PTK2B DOCK7 EXOC7 EXOC8 EXOC4	8.55e-04	253	61	5	GO:0030427
GeneOntologyCellularComponent	RSC-type complex	SMARCC1 SMARCC2	8.58e-04	15	61	2	GO:0016586
GeneOntologyCellularComponent	nBAF complex	SMARCC1 SMARCC2	9.79e-04	16	61	2	GO:0071565
GeneOntologyCellularComponent	cytoplasmic ribonucleoprotein granule	RBM4 STAU2 APOBEC3G CNOT1 APOBEC3F	1.12e-03	269	61	5	GO:0036464
GeneOntologyCellularComponent	vesicle tethering complex	EXOC7 EXOC8 EXOC4	1.22e-03	72	61	3	GO:0099023
GeneOntologyCellularComponent	ribonucleoprotein granule	RBM4 STAU2 APOBEC3G CNOT1 APOBEC3F	1.50e-03	287	61	5	GO:0035770
GeneOntologyCellularComponent	distal axon	PTK2B DOCK7 RIMBP2 EXOC7 EXOC8 EXOC4	1.66e-03	435	61	6	GO:0150034
GeneOntologyCellularComponent	telomerase holoenzyme complex	NOP10 HNRNPCL3	2.41e-03	25	61	2	GO:0005697
GeneOntologyCellularComponent	P-body	APOBEC3G CNOT1 APOBEC3F	3.31e-03	102	61	3	GO:0000932
GeneOntologyCellularComponent	chromatin	MMS22L ERF SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV AKAP8L DNMT3B PROX1	3.38e-03	1480	61	11	GO:0000785
GeneOntologyCellularComponent	SWI/SNF complex	SMARCC1 SMARCC2	3.46e-03	30	61	2	GO:0016514
Domain	ETS_DOMAIN_1	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	PS00345
Domain	ETS_DOMAIN_2	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	PS00346
Domain	ETS	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	SM00413
Domain	Ets_dom	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	IPR000418
Domain	ETS_DOMAIN_3	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	PS50061
Domain	Ets	ERF ELF1 ELF2 ELF4 FEV	2.46e-08	28	59	5	PF00178
Domain	Elf-1_N	ELF1 ELF2 ELF4	2.99e-08	3	59	3	PF12310
Domain	TF_Elf_N	ELF1 ELF2 ELF4	2.99e-08	3	59	3	IPR022084
Domain	-	ERF SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV PREX2	4.03e-07	218	59	8	1.10.10.10
Domain	WHTH_DNA-bd_dom	ERF SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV PREX2	8.88e-07	242	59	8	IPR011991
Domain	SMARCC_C	SMARCC1 SMARCC2	9.81e-06	2	59	2	IPR032451
Domain	SMARCC_N	SMARCC1 SMARCC2	9.81e-06	2	59	2	IPR032450
Domain	SWIRM-assoc	SMARCC1 SMARCC2	9.81e-06	2	59	2	IPR032448
Domain	SWIRM-assoc_2	SMARCC1 SMARCC2	9.81e-06	2	59	2	PF16496
Domain	SWIRM-assoc_1	SMARCC1 SMARCC2	9.81e-06	2	59	2	PF16495
Domain	SWIRM-assoc_3	SMARCC1 SMARCC2	9.81e-06	2	59	2	PF16498
Domain	SWIRM	SMARCC1 SMARCC2	1.46e-04	6	59	2	PS50934
Domain	SWIRM	SMARCC1 SMARCC2	1.46e-04	6	59	2	PF04433
Domain	SWIRM	SMARCC1 SMARCC2	1.46e-04	6	59	2	IPR007526
Domain	Syndecan	NRXN3 NRXN2	2.04e-04	7	59	2	PF01034
Domain	Syndecan/Neurexin_dom	NRXN3 NRXN2	2.04e-04	7	59	2	IPR027789
Domain	Glyco_transf_8	GLT8D2 UGGT2	4.34e-04	10	59	2	PF01501
Domain	Glyco_trans_8	GLT8D2 UGGT2	4.34e-04	10	59	2	IPR002495
Domain	DOCK_C	DOCK2 DOCK7	5.30e-04	11	59	2	IPR010703
Domain	DHR-1_domain	DOCK2 DOCK7	5.30e-04	11	59	2	IPR027007
Domain	DHR_2	DOCK2 DOCK7	5.30e-04	11	59	2	PS51651
Domain	DHR_1	DOCK2 DOCK7	5.30e-04	11	59	2	PS51650
Domain	DOCK-C2	DOCK2 DOCK7	5.30e-04	11	59	2	PF14429
Domain	DHR-2	DOCK2 DOCK7	5.30e-04	11	59	2	IPR027357
Domain	DHR-2	DOCK2 DOCK7	5.30e-04	11	59	2	PF06920
Domain	DOCK	DOCK2 DOCK7	5.30e-04	11	59	2	IPR026791
Domain	APOBEC_N	APOBEC3G APOBEC3F	6.34e-04	12	59	2	PF08210
Domain	Cullin_repeat-like_dom	EXOC7 EXOC8	6.34e-04	12	59	2	IPR016159
Domain	APOBEC_N	APOBEC3G APOBEC3F	6.34e-04	12	59	2	IPR013158
Domain	APOBEC/CMP_deaminase_Zn-bd	APOBEC3G APOBEC3F	8.71e-04	14	59	2	IPR016192
Domain	Neurexin-like	NRXN3 NRXN2	8.71e-04	14	59	2	IPR003585
Domain	4.1m	NRXN3 NRXN2	8.71e-04	14	59	2	SM00294
Domain	CYT_DCMP_DEAMINASES_2	APOBEC3G APOBEC3F	1.00e-03	15	59	2	PS51747
Domain	Cytidine_deaminase-like	APOBEC3G APOBEC3F	1.29e-03	17	59	2	IPR016193
Domain	CYT_DCMP_DEAMINASES_1	APOBEC3G APOBEC3F	1.29e-03	17	59	2	PS00903
Domain	CMP_dCMP_Zn-bd	APOBEC3G APOBEC3F	1.29e-03	17	59	2	IPR002125
Domain	zf-CCHC	RBM4B RBM4	2.38e-03	23	59	2	PF00098
Domain	-	RBM4B RBM4	3.04e-03	26	59	2	4.10.60.10
Domain	SANT_dom	SMARCC1 SMARCC2	3.04e-03	26	59	2	IPR017884
Domain	SANT	SMARCC1 SMARCC2	3.52e-03	28	59	2	PS51293
Domain	BRCT_dom	SMARCC1 SMARCC2	3.52e-03	28	59	2	IPR001357
Pathway	REACTOME_INSULIN_PROCESSING	EXOC7 EXOC8 EXOC4	9.70e-06	13	47	3	MM14909
Pathway	REACTOME_VXPX_CARGO_TARGETING_TO_CILIUM	EXOC7 EXOC8 EXOC4	3.81e-05	20	47	3	MM15208
Pathway	REACTOME_VXPX_CARGO_TARGETING_TO_CILIUM	EXOC7 EXOC8 EXOC4	4.43e-05	21	47	3	M27479
Pathway	REACTOME_INSULIN_PROCESSING	EXOC7 EXOC8 EXOC4	7.59e-05	25	47	3	M27198
Pathway	REACTOME_RUNX1_REGULATES_TRANSCRIPTION_OF_GENES_INVOLVED_IN_BCR_SIGNALING	ELF1 ELF2	1.62e-04	6	47	2	M27798
Pathway	REACTOME_CARGO_TRAFFICKING_TO_THE_PERICILIARY_MEMBRANE	EXOC7 EXOC8 EXOC4	2.92e-04	39	47	3	MM15209
Pathway	WP_NF1_COPY_NUMBER_VARIATION_SYNDROME	EGFR EXOC7 EXOC8 EXOC4	4.67e-04	109	47	4	M48084
Pathway	PID_ARF6_TRAFFICKING_PATHWAY	ITGA9 EXOC7 EXOC4	5.75e-04	49	47	3	M67
Pathway	REACTOME_CARGO_TRAFFICKING_TO_THE_PERICILIARY_MEMBRANE	EXOC7 EXOC8 EXOC4	6.47e-04	51	47	3	M27480
Pathway	BIOCARTA_HSWI_SNF_PATHWAY	SMARCC1 SMARCC2	7.03e-04	12	47	2	M22006
Pathway	WP_CILIARY_LANDSCAPE	ERF EXOC7 CNOT1 EXOC8 EXOC4	7.18e-04	215	47	5	M39734
Pubmed	MECP2 directly interacts with RNA polymerase II to modulate transcription in human neurons.	ABCF1 KIDINS220 NRXN2 RPN1 RBM4 STAU2 DOCK7 SMARCC1 SMARCC2 FBXO11 SIPA1L2 CNOT1 AKAP8L DNMT3B PROX1	4.16e-10	1082	61	15	38697112
Pubmed	ETS-dependent regulation of a distal Gata4 cardiac enhancer.	ERF ELF1 ELF2 ELF4 FEV	5.81e-10	24	61	5	22056786
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	ABCF1 ERF DOCK7 SMARCC1 HNRNPCL4 UGGT2 EXOC7 AKAP8L EXOC8 HNRNPCL3 EXOC4 ITPR1	1.24e-09	650	61	12	38777146
Pubmed	ETS-family genes in pancreatic development.	ERF ELF1 ELF2 ELF4 FEV	1.61e-09	29	61	5	17907201
Pubmed	Articular cartilage endurance and resistance to osteoarthritic changes require transcription factor Erg.	ERF ELF1 ELF2 ELF4 FEV	1.61e-09	29	61	5	26097038
Pubmed	Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias.	ELF1 ELF2 ELF4	5.12e-08	5	61	3	10207087
Pubmed	Arl13b and the exocyst interact synergistically in ciliogenesis.	EXOC7 EXOC8 EXOC4	1.02e-07	6	61	3	26582389
Pubmed	Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene.	ELF1 ELF2 ELF4	1.02e-07	6	61	3	14970218
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	DNAJB12 EGFR RBM4B RBM4 STAU2 FBXO11 CNOT1 AKAP8L HNRNPCL3	1.12e-07	462	61	9	31138677
Pubmed	The exocyst complex is required for targeting of Glut4 to the plasma membrane by insulin.	EXOC7 EXOC8 EXOC4	4.28e-07	9	61	3	12687004
Pubmed	The brain exocyst complex interacts with RalA in a GTP-dependent manner: identification of a novel mammalian Sec3 gene and a second Sec15 gene.	EXOC7 EXOC8 EXOC4	4.28e-07	9	61	3	11406615
Pubmed	Exorcising the exocyst complex.	EXOC7 EXOC8 EXOC4	4.28e-07	9	61	3	22420621
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	ABCF1 RPN1 UBE3A RABGAP1L STAU2 DOCK7 SMARCC2 SIPA1L2 CNOT1 AKAP8L PDXK ITPR1	5.69e-07	1139	61	12	36417873
Pubmed	Ral GTPases regulate exocyst assembly through dual subunit interactions.	EXOC7 EXOC8 EXOC4	6.11e-07	10	61	3	14525976
Pubmed	Defining the membrane proteome of NK cells.	DOCK2 DNAJB12 ABCF1 KIDINS220 RPN1 STAU2 ERMP1 EXOC7 CNOT1 EXOC8 EXOC4 ITPR1	7.42e-07	1168	61	12	19946888
Pubmed	Characterization of the EGFR interactome reveals associated protein complex networks and intracellular receptor dynamics.	DNAJB12 EGFR RPN1 EXOC7 EXOC8 EXOC4	8.54e-07	183	61	6	23956138
Pubmed	Human transcription factor protein interaction networks.	ERF RPN1 RBM4 STAU2 SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV CNOT1 AKAP8L EXOC4	9.39e-07	1429	61	13	35140242
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	PTK2B ABCF1 KIDINS220 NRXN2 RPN1 DOCK7 SMARCC2 RIMBP2 SIPA1L2 CNOT1 PDXK HNRNPCL3 EXOC4	9.54e-07	1431	61	13	37142655
Pubmed	∆F508 CFTR interactome remodelling promotes rescue of cystic fibrosis.	DNAJB12 EPPK1 EGFR RPN1 SMARCC2 EXOC7 PDXK EXOC8 EXOC4	1.85e-06	647	61	9	26618866
Pubmed	Short Communication: Expression of APOBEC3G and Interferon Gamma in Pleural Fluid Mononuclear Cells from HIV/TB Dual Infected Subjects.	PTK2B APOBEC3G APOBEC3F	2.83e-06	16	61	3	25924204
Pubmed	Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17428847
Pubmed	Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	26482266
Pubmed	miR-7/EGFR/MEGF9 axis regulates cartilage degradation in osteoarthritis via PI3K/AKT/mTOR signaling pathway.	MEGF9 EGFR	3.03e-06	2	61	2	34629037
Pubmed	Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19944180
Pubmed	Dispersed sites of HIV Vif-dependent polyubiquitination in the DNA deaminase APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	23318957
Pubmed	Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20299747
Pubmed	Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17522216
Pubmed	Cloning of a novel human ELF-1-related ETS transcription factor, ELFR, its characterization and chromosomal assignment relative to ELF-1.	ELF1 ELF4	3.03e-06	2	61	2	9524226
Pubmed	Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18619467
Pubmed	Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20610708
Pubmed	Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55(GAG)) of the virion nucleocapsid proteins.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19826902
Pubmed	The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	15647250
Pubmed	The Swi3 protein plays a unique role in regulating respiration in eukaryotes.	SMARCC1 SMARCC2	3.03e-06	2	61	2	27190130
Pubmed	Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	16501124
Pubmed	HIV-1 Vif: counteracting innate antiretroviral defenses.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	14565218
Pubmed	Comparison of cellular ribonucleoprotein complexes associated with the APOBEC3F and APOBEC3G antiviral proteins.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18367521
Pubmed	Antiviral roles of APOBEC proteins against HIV-1 and suppression by Vif.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19669862
Pubmed	Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	25590131
Pubmed	Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19535447
Pubmed	Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	26048885
Pubmed	Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20624919
Pubmed	Phylogenetic and molecular characterization of the splicing factor RBM4.	RBM4B RBM4	3.03e-06	2	61	2	23527094
Pubmed	RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17609216
Pubmed	Pyk2 activation triggers epidermal growth factor receptor signaling and cell motility after wounding sheets of epithelial cells.	PTK2B EGFR	3.03e-06	2	61	2	20215112
Pubmed	Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19036809
Pubmed	Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19587057
Pubmed	Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17142455
Pubmed	A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	15152192
Pubmed	Human APOBEC3F incorporation into human immunodeficiency virus type 1 particles.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	25038404
Pubmed	Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	24185281
Pubmed	Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20335268
Pubmed	Reduced kinase D‑interacting substrate of 220 kDa (Kidins220) in pancreatic cancer promotes EGFR/ERK signalling and disease progression.	KIDINS220 EGFR	3.03e-06	2	61	2	33955519
Pubmed	Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	24722422
Pubmed	Inhibition of LINE-1 and Alu retrotransposition by exosomes encapsidating APOBEC3G and APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20153011
Pubmed	Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	27881650
Pubmed	APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17145955
Pubmed	Repression of porcine endogenous retrovirus infection by human APOBEC3 proteins.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	21396348
Pubmed	A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	15054139
Pubmed	Inhibition of hepatitis B virus replication by APOBEC3G.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	15031497
Pubmed	Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	24503066
Pubmed	APOBEC3 proteins and reverse transcription.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18262674
Pubmed	Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	24651717
Pubmed	Death and the retrovirus.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	14557052
Pubmed	Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20686027
Pubmed	High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	25985400
Pubmed	APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17121840
Pubmed	Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	24623435
Pubmed	The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum.	RBM4B RBM4	3.03e-06	2	61	2	18708123
Pubmed	E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	22695298
Pubmed	Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19169351
Pubmed	APOBEC3F and APOBEC3G inhibit HIV-1 DNA integration by different mechanisms.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20219927
Pubmed	Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20592068
Pubmed	Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	17459442
Pubmed	Differential sensitivity of porcine endogenous retrovirus to APOBEC3-mediated inhibition.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	26016442
Pubmed	The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20844042
Pubmed	Molecular docking analysis of RN18 and VEC5 in A3G-Vif inhibition.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	25489169
Pubmed	Characterization of NERF, a novel transcription factor related to the Ets factor ELF-1.	ELF1 ELF2	3.03e-06	2	61	2	8756667
Pubmed	Stably expressed APOBEC3F has negligible antiviral activity.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	20702622
Pubmed	T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	23536679
Pubmed	Unusual substitutions in HIV-1 vif from children infected perinatally without progression to AIDS for more than 8 years without therapy.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	23080486
Pubmed	Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	19487726
Pubmed	APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	16641889
Pubmed	Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18448538
Pubmed	Expression of APOBEC3G/3F and G-to-A hypermutation levels in HIV-1-infected children with different profiles of disease progression.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	21897871
Pubmed	APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18604271
Pubmed	Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	18603011
Pubmed	Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	16940537
Pubmed	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.	APOBEC3G APOBEC3F	3.03e-06	2	61	2	16460778
Pubmed	Transcriptome analysis of mouse stem cells and early embryos.	MMS22L RBM4 STAU2 FBXO11 ITGA9 HNRNPCL3 ITPR1	3.42e-06	363	61	7	14691545
Pubmed	RalB and the exocyst mediate the cellular starvation response by direct activation of autophagosome assembly.	EXOC7 EXOC8 EXOC4	3.43e-06	17	61	3	21241894
Pubmed	Identification of the hypoxia-inducible factor 2α nuclear interactome in melanoma cells reveals master proteins involved in melanoma development.	SMARCC1 SMARCC2 CNOT1 AKAP8L	5.69e-06	66	61	4	23275444
Pubmed	The E3 ubiquitin ligase HECTD1 contributes to cell proliferation through an effect on mitosis.	ABCF1 RPN1 RBM4 STAU2 FBXO11 EXOC7 CNOT1 AKAP8L EXOC4	6.74e-06	759	61	9	35915203
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	KIDINS220 MEGF9 RABGAP1L DOCK7 RIMBP2 SIPA1L2 KLHL32	7.23e-06	407	61	7	12693553
Pubmed	The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.	APOBEC3G APOBEC3F	9.07e-06	3	61	2	22013041
Pubmed	Conditional Knockout of Neurexins Alters the Contribution of Calcium Channel Subtypes to Presynaptic Ca2+ Influx.	NRXN3 NRXN2	9.07e-06	3	61	2	38891114
Pubmed	Enhancing immunity to HIV through APOBEC.	APOBEC3G APOBEC3F	9.07e-06	3	61	2	18846074
Pubmed	SH3BP1, an exocyst-associated RhoGAP, inactivates Rac1 at the front to drive cell motility.	EXOC8 EXOC4	9.07e-06	3	61	2	21658605
Pubmed	HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.	APOBEC3G APOBEC3F	9.07e-06	3	61	2	24942576
Pubmed	Carbachol-stimulated transactivation of epidermal growth factor receptor and mitogen-activated protein kinase in T(84) cells is mediated by intracellular Ca2+, PYK-2, and p60(src).	PTK2B EGFR	9.07e-06	3	61	2	10777553
Pubmed	alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction.	NRXN3 NRXN2	9.07e-06	3	61	2	16406382
Interaction	ARID4B interactions	EGFR SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV	2.29e-06	199	61	7	int:ARID4B
Interaction	MECP2 interactions	ABCF1 KIDINS220 NRXN2 RPN1 RBM4 STAU2 DOCK7 SMARCC1 SMARCC2 FBXO11 SIPA1L2 CNOT1 AKAP8L DNMT3B PROX1	4.79e-06	1287	61	15	int:MECP2
Interaction	TAF5 interactions	EGFR ELF1 ELF2 ELF4 FEV	6.20e-06	86	61	5	int:TAF5
Interaction	TAF6 interactions	EGFR SMARCC1 SMARCC2 ELF1 ELF2 ELF4 FEV	8.99e-06	245	61	7	int:TAF6
Interaction	DPF1 interactions	EGFR RPN1 SMARCC1 SMARCC2 FEV	1.01e-05	95	61	5	int:DPF1
Interaction	EXOC6B interactions	EGFR EXOC7 EXOC8 EXOC4	1.03e-05	45	61	4	int:EXOC6B
Interaction	ACTR6 interactions	ELF1 ELF2 ELF4 FEV	1.23e-05	47	61	4	int:ACTR6
Interaction	E2F6 interactions	SMARCC1 ELF1 ELF2 ELF4 FEV DNMT3B	2.01e-05	185	61	6	int:E2F6
Interaction	BAP1 interactions	ABCF1 EPPK1 EGFR RBM4 STAU2 DOCK7 ELF1 ELF2 ELF4 FEV EXOC7 CNOT1 AKAP8L WDTC1	2.91e-05	1314	61	14	int:BAP1
Interaction	SRCAP interactions	SMARCC1 SMARCC2 ELF1 ELF2 ELF4	4.12e-05	127	61	5	int:SRCAP
Interaction	RNF43 interactions	DNAJB12 KIDINS220 RBM4 TDO2 SIPA1L2 CNOT1 AKAP8L EXOC4	4.19e-05	427	61	8	int:RNF43
Interaction	KMT2A interactions	RPN1 ASB7 SMARCC1 SMARCC2 ELF1 ELF2 FEV	4.42e-05	314	61	7	int:KMT2A
Interaction	GABPA interactions	EGFR ELF1 ELF2 ELF4 FEV	4.60e-05	130	61	5	int:GABPA
Interaction	ING2 interactions	SMARCC1 SMARCC2 ELF1 ELF2	5.35e-05	68	61	4	int:ING2
Interaction	ZHX2 interactions	ELF1 ELF2 ELF4 FEV	5.67e-05	69	61	4	int:ZHX2
Interaction	KANSL2 interactions	EGFR ELF1 ELF2 ELF4	6.00e-05	70	61	4	int:KANSL2
Interaction	KIF20A interactions	ABCF1 EPPK1 KIDINS220 RBM4B ASB7 RBM4 RABGAP1L SMARCC2 AKAP8L HNRNPCL3 ITPR1 APOBEC3F	6.24e-05	1052	61	12	int:KIF20A
Interaction	PHF10 interactions	SMARCC1 SMARCC2 ELF1 ELF4 FEV	6.33e-05	139	61	5	int:PHF10
Interaction	VPS72 interactions	EGFR ELF1 ELF2 ELF4 FEV	8.00e-05	146	61	5	int:VPS72
Interaction	AWAT2 interactions	EGFR UBE3A	8.96e-05	5	61	2	int:AWAT2
Interaction	ARID2 interactions	SMARCC1 SMARCC2 ELF1 ELF4 FEV	9.98e-05	153	61	5	int:ARID2
Interaction	STAT2 interactions	EGFR SMARCC1 SMARCC2 FBXO11	1.06e-04	81	61	4	int:STAT2
Interaction	EXOC6 interactions	EGFR EXOC7 EXOC8 EXOC4	1.17e-04	83	61	4	int:EXOC6
Interaction	PBRM1 interactions	UBE3A SMARCC1 SMARCC2 ELF1 ELF4 FEV	1.28e-04	258	61	6	int:PBRM1
Interaction	MYBL2 interactions	EGFR RPN1 ELF2 ELF4 FEV	1.31e-04	162	61	5	int:MYBL2
Interaction	KANSL3 interactions	EGFR ELF1 ELF2 ELF4	1.34e-04	86	61	4	int:KANSL3
Interaction	NBPF14 interactions	EGFR UBE3A	1.34e-04	6	61	2	int:NBPF14
Interaction	INO80 interactions	EGFR ELF1 ELF2 ELF4	1.40e-04	87	61	4	int:INO80
Interaction	TAF3 interactions	ELF1 ELF2 ELF4 FEV	1.46e-04	88	61	4	int:TAF3
Interaction	BMI1 interactions	RPN1 UBE3A STAU2 DOCK7 SMARCC1 NOP10 AKAP8L DNMT3B APOBEC3F	1.54e-04	659	61	9	int:BMI1
Interaction	MKRN2 interactions	EGFR RBM4B RBM4 STAU2 CNOT1 PROX1 WDTC1	1.58e-04	385	61	7	int:MKRN2
Interaction	CPSF2 interactions	EGFR ASB7 SMARCC1 SMARCC2 WDTC1	1.77e-04	173	61	5	int:CPSF2
Interaction	DNAJB12 interactions	DNAJB12 EGFR RPN1 UGGT2 WDTC1	1.82e-04	174	61	5	int:DNAJB12
Interaction	LIN54 interactions	ELF1 ELF2 ELF4 FEV	1.89e-04	94	61	4	int:LIN54
Interaction	KLF1 interactions	RBM4B SMARCC1 SMARCC2	1.91e-04	37	61	3	int:KLF1
Interaction	TAF2 interactions	EGFR ELF1 ELF2 ELF4 FEV	2.03e-04	178	61	5	int:TAF2
Interaction	KANSL1 interactions	EGFR ELF1 ELF2 ELF4	2.05e-04	96	61	4	int:KANSL1
Interaction	ZNF366 interactions	UBE3A AKAP8L	2.49e-04	8	61	2	int:ZNF366
Interaction	SCML4 interactions	FBXO11 WDTC1	2.49e-04	8	61	2	int:SCML4
Interaction	ING1 interactions	SMARCC1 SMARCC2 ELF2 EXOC4	2.68e-04	103	61	4	int:ING1
Interaction	WDR75 interactions	EGFR RBM4B ASB7 RBM4	2.79e-04	104	61	4	int:WDR75
Interaction	IFI16 interactions	ABCF1 EGFR RBM4B RABGAP1L DOCK7 SMARCC1 SMARCC2 CNOT1 HNRNPCL3	2.79e-04	714	61	9	int:IFI16
Interaction	HELLS interactions	MMS22L EGFR RABGAP1L UGGT2 DNMT3B	2.88e-04	192	61	5	int:HELLS
Interaction	ALG2 interactions	PTK2B EGFR WDTC1	3.20e-04	44	61	3	int:ALG2
Interaction	OST4 interactions	DNAJB12 RPN1 RBM4B STAU2	3.33e-04	109	61	4	int:OST4
Interaction	PHF12 interactions	ELF1 ELF2 ELF4 FEV	3.45e-04	110	61	4	int:PHF12
Cytoband	6q16.1	MMS22L KLHL32	2.62e-04	18	61	2	6q16.1
Cytoband	1q42.2	SIPA1L2 EXOC8	5.11e-04	25	61	2	1q42.2
Cytoband	11q13	NRXN2 RBM4B RBM4	5.34e-04	118	61	3	11q13
Cytoband	Ensembl 112 genes in cytogenetic band chr6q16	MMS22L KLHL32	2.55e-03	56	61	2	chr6q16
GeneFamily	ETS transcription factor family	ERF ELF1 ELF2 ELF4 FEV	5.00e-09	28	42	5	534
GeneFamily	Exocyst complex	EXOC7 EXOC8 EXOC4	9.70e-07	9	42	3	1055
GeneFamily	Apolipoprotein B mRNA editing enzyme catalytic subunits	APOBEC3G APOBEC3F	3.43e-04	12	42	2	406
GeneFamily	Zinc fingers CCHC-type\|RNA binding motif containing	RBM4B RBM4	1.53e-03	25	42	2	74
GeneFamily	GATA zinc finger domain containing\|Myb/SANT domain containing	SMARCC1 SMARCC2	6.73e-03	53	42	2	532
GeneFamily	Armadillo repeat containing\|Protein phosphatase 1 regulatory subunits	RIMBP2 PREX2 ITPR1	8.51e-03	181	42	3	694
Coexpression	GSE40274_EOS_VS_FOXP3_AND_EOS_TRANSDUCED_ACTIVATED_CD4_TCELL_DN	SPTLC3 NRXN2 TDO2 SPAG17 KLHL32	7.91e-06	121	59	5	M9153
Coexpression	ZAK_PBMC_MRKAD5_HIV_1_GAG_POL_NEF_AGE_20_50YO_1DY_ADDNL_EXON_LVL_UP	PTK2B RABGAP1L APOBEC3G APOBEC3F	6.07e-05	94	59	4	M40880
Coexpression	GSE26488_HDAC7_KO_VS_VP16_TRANSGENIC_HDAC7_KO_DOUBLE_POSITIVE_THYMOCYTE_UP	KIDINS220 ERF IFNE ELF2 KLHL32	6.92e-05	190	59	5	M8190
Coexpression	GSE7548_NAIVE_VS_DAY7_PCC_IMMUNIZATION_CD4_TCELL_DN	PTK2B RBM4 RABGAP1L APOBEC3G ELF4	8.61e-05	199	59	5	M6837
Coexpression	GSE2197_IMMUNOSUPPRESSIVE_DNA_VS_UNTREATEDIN_DC_DN	SPTLC3 MEGF9 ASB7 ELF2 AKAP8L	8.61e-05	199	59	5	M4390
Coexpression	GSE23505_IL6_IL1_VS_IL6_IL1_TGFB_TREATED_CD4_TCELL_DN	MMS22L NOP10 ERMP1 EXOC7 EXOC4	8.82e-05	200	59	5	M7861
Coexpression	GSE7509_DC_VS_MONOCYTE_WITH_FCGRIIB_STIM_UP	MEGF9 SMARCC1 SMARCC2 ITPR1 WDTC1	8.82e-05	200	59	5	M6832
Coexpression	STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP	PTK2B NRXN3 MEGF9 SMARCC2 RIMBP2	1.01e-04	206	59	5	M2817
Coexpression	STARK_PREFRONTAL_CORTEX_22Q11_DELETION_UP	PTK2B NRXN3 MEGF9 SMARCC2 RIMBP2	1.06e-04	208	59	5	MM581
ToppCell	10x5'-Lung-Lymphocytic_T_CD4/8-lo-Trm_Tgd\|Lung / Manually curated celltypes from each tissue	MMS22L ERFL ASB7 STAU2 APOBEC3F	3.34e-06	167	61	5	dcbcc658082910838c8082d71a64917055086cc4
ToppCell	facs-Trachea-18m-Endothelial-endothelial_cell_of_trachea-tracheal_endothelial_cell-tracheal_endothelial_cell_l54\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	NRXN2 TDO2 PREX2 DNMT3B PROX1	5.50e-06	185	61	5	59acaf025353405948dc34ccccf37ec5c08ea903
ToppCell	renal_medulla_nuclei-Hypertensive_with+without-CKD-Endothelial-blood_vessel_endothelial_cell_of_kidney-capillary-immature_endothelial_cell-Peritubular_Capilary_Endothelial_Cell__prolif\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	ELF4 ADAM32 ITGA9 CHST8	6.07e-05	155	61	4	59035d792c26d870a8b097939e97fa47859ba68c
ToppCell	frontal_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Plch2_Dock5\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	EGFR RIMBP2 ITGA9 PROX1	6.38e-05	157	61	4	516903469756c5fabfdf56d7bd59b3bdd7b44e39
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_1\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	EGFR ERMP1 TDO2 PDXK	6.54e-05	158	61	4	1cefb82b9bf79c687a119be568cfc15b14c6e040
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Lamp5-Lamp5_Lsp1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	EGFR RIMBP2 ITGA9 PROX1	6.70e-05	159	61	4	0dccc4275b9b4f8554dd556da7218e130bff8fd1
ToppCell	saliva-Severe-critical_progression_d28-40-Myeloid-Macrophage-macrophage,_alveolar-Macro_c6-VCAN\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	PHOSPHO1 RPN1 APOBEC3G APOBEC3F	6.86e-05	160	61	4	8374ae912337947b2cc8d17d5840f306361fe1ff
ToppCell	Endothelial-B-IPF_01\|World / lung cells shred on cell class, cell subclass, sample id	GLT8D2 PREX2 CHST8 PROX1	7.92e-05	166	61	4	c286987ea4e511195607c87ec4529c2c2ed2122e
ToppCell	3'-GW_trimst-1.5-SmallIntestine-Epithelial-neuro-epithelial\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IFNE RIMBP2 FEV KLHL32	9.29e-05	173	61	4	46ed379571385684145b5cb6dd4ae340ac546e64
ToppCell	3'-GW_trimst-1-SmallIntestine-Epithelial-neuro-epithelial-D_cells_(SST+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RIMBP2 FEV TDO2 PROX1	9.50e-05	174	61	4	019eae059bd9eb107dee8f0d0f574ca36c2c26e1
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_GGH\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR PREX2 HNRNPCL3 PROX1	9.92e-05	176	61	4	23f930dac5247ea6d4124da33933d61ad6e089af
ToppCell	5'-GW_trimst-1.5-SmallIntestine-Epithelial-neuro-epithelial-D_cells_(SST+)\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RIMBP2 FEV TDO2 PROX1	1.01e-04	177	61	4	8dbef0005095c01a806d8c7f723dc48a4650efec
ToppCell	343B-Lymphocytic-NK_cells-NK_cell_D\|NK_cells / Donor, Lineage, Cell class and subclass (all cells)	EGFR PREX2 PROX1	1.02e-04	66	61	3	57fd31a25addc48793d7975eadccf4c5a41a8b03
ToppCell	renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	EGFR ERMP1 TDO2 PDXK	1.04e-04	178	61	4	c20f050344a2e120e685e2a7fe36c6dfc1dc37b6
ToppCell	COVID-19_Severe-Hematopoietic_SC-HSPC\|COVID-19_Severe / Disease group, lineage and cell class	SPTLC3 ITGA9 PREX2 DNMT3B	1.15e-04	183	61	4	4146b1c0e5f76d25226745abfa28f77127a444fc
ToppCell	5'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_differentiating-Lymphatic_EC_differentiating_L.2.5.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GLT8D2 ITGA9 CHST8 PROX1	1.15e-04	183	61	4	4d16bfbadf2cd13008c35e23dd2b5b4ecf92ee11
ToppCell	COVID-19_Severe-Hematopoietic_SC\|COVID-19_Severe / Disease group, lineage and cell class	SPTLC3 ITGA9 PREX2 DNMT3B	1.15e-04	183	61	4	92aab7ce65aca17988bc2add4ff9fb8384e2c21b
ToppCell	PBMC-Severe-Hematopoietic-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	a6169613c6493b947a176493f542368bfa935dab
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	51d0447699e3b8f01abbde83f26b748bc9f3c723
ToppCell	3'-GW_trimst-1-SmallIntestine-Epithelial-neuro-epithelial-I_cells_(CCK+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	RIMBP2 FEV TDO2 PROX1	1.18e-04	184	61	4	1e6f86f9e379cd9f453f6b7185f681b44eb63e09
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	f7b0bb45a9055ab34e98b251217f6ec38c75ca22
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	cc01c19180861f491a8dc16d60fabd1215fc4525
ToppCell	PBMC-Severe-Hematopoietic-HSPC-HSPC-\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	492c680f0769ba4e651d09c2e8e5d5d271ed08aa
ToppCell	PBMC-Severe-Hematopoietic-HSPC\|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09)	SPTLC3 ITGA9 PREX2 DNMT3B	1.18e-04	184	61	4	26edbf84216538b80f1ffcc079ee6e385a71fbf9
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_1-Inh_L1_ADARB2_ADAM33\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR SIPA1L2 PREX2 PROX1	1.20e-04	185	61	4	487fa382232564f075960899d50afa0edae5d258
ToppCell	CV-Moderate-7\|Moderate / Virus stimulation, Condition and Cluster	MMS22L KIDINS220 ERMP1 EXOC4	1.20e-04	185	61	4	a6c9203ce6c2892a4a369c9bcfb85720f01cbb3f
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.23e-04	186	61	4	310d16f4e5cffee3ea6d7635508c513a3b92131e
ToppCell	CV-Moderate-7\|CV / Virus stimulation, Condition and Cluster	MMS22L KIDINS220 ERMP1 EXOC4	1.23e-04	186	61	4	8571956890fc9894d766ba294a28e376b4aba428
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.28e-04	188	61	4	0501a8aa850bd2e347020abd1cac4d8075738189
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.31e-04	189	61	4	f0aaf2994d319a39877d2845eaab9f166adead4e
ToppCell	Adult\|World / Lineage, Cell type, age group and donor	DOCK2 PTK2B NRXN3 MEGF9	1.31e-04	189	61	4	5cd285bfad973125d46d704fec18b21266a63379
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	GLT8D2 ITGA9 CHST8 PROX1	1.33e-04	190	61	4	876bd2eb9ed2624cb23bdcf6b989e4fa34d099e3
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.33e-04	190	61	4	56cc761e50fddfb5366391518b4d8e16589b6b42
ToppCell	wk_08-11-Epithelial-Proximal_epithelial-intermediate_neuroendocrine\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	RIMBP2 FEV KLHL32 PROX1	1.33e-04	190	61	4	5f1863bce9400b7c932f0e4d0e012ec4e8d7e555
ToppCell	Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1\|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.33e-04	190	61	4	25d4b591f75c26e404a34c42f1742d580af6598d
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell_of_renal_cortex-lymphatic_endothelial_cell_of_renal_cortex\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	GLT8D2 ITGA9 CHST8 PROX1	1.33e-04	190	61	4	be9f36127028f52ca5fc1b32ba15a6c26aad69ac
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Endothelial-lymphatic_endothelial_cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	GLT8D2 ITGA9 CHST8 PROX1	1.33e-04	190	61	4	09a8855901c3c9332dbaab3e40166485b696d0f1
ToppCell	Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.36e-04	191	61	4	7b386512284dfaa0e95358b28ee82632ee965e64
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L1_LAMP5_NDNF\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.36e-04	191	61	4	fa50a3c7ff86e1ee07100da1ace0b0fa1b0ab26b
ToppCell	3'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_mature\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GLT8D2 ITGA9 CHST8 PROX1	1.39e-04	192	61	4	291df12b4b5ff11fbaa43033692b8f4b5cdf65a1
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.39e-04	192	61	4	f6ec683b2133b3095a1fcc06ca8605cf38f774b5
ToppCell	3'-Parenchyma_lung-Endothelial-Lymphatic_EC-endothelial_cell_of_lymphatic_vessel-Lymphatic_EC_mature-Lymphatic_EC_mature_L.2.5.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	GLT8D2 ITGA9 CHST8 PROX1	1.39e-04	192	61	4	35ffe7aa9ffab85eac3326651e901c39d0119650
ToppCell	primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_1\|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.39e-04	192	61	4	690b3d17c481159bc96b8bc7f6a66b51343ee858
ToppCell	droplet-Pancreas-Endocrine-18m-Epithelial-pancreatic_D_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRXN2 FEV CHST8 ITPR1	1.41e-04	193	61	4	6995ee29bf403a71247de92a37dfd851be5acf2e
ToppCell	facs-Liver-Liver_non-hepato/SCs-18m-Endothelial-nan\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GLT8D2 NRXN2 ITGA9 PREX2	1.41e-04	193	61	4	2483bb7f398e4fa0ef09c8bd584ed25703853f03
ToppCell	wk_08-11-Hematologic-Meg-ery-Definitive_erythroblast\|wk_08-11 / Celltypes from embryonic and fetal-stage human lung	PTK2B PHOSPHO1 ASB7 AKAP8L	1.41e-04	193	61	4	be75abfdf5301cf33df8ee9ed92504d44fdf19a6
ToppCell	droplet-Pancreas-Endocrine-18m-Epithelial-pancreatic_D_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	NRXN2 FEV CHST8 ITPR1	1.41e-04	193	61	4	7fcfb0f76789fa8d8caa18304cb43c8fd899a81b
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.44e-04	194	61	4	52aebb0b563e2c2058e7f0554ae870e47692b163
ToppCell	Anterior_Cingulate_gyrus_(CgG)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5\|Anterior_Cingulate_gyrus_(CgG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	EGFR RIMBP2 PREX2 PROX1	1.44e-04	194	61	4	bd06e2b8d8c06cddf2e4f58849b86e09013acae1
ToppCell	HSPCs-Mk_prog.\|World / Lineage and Cell class	RABGAP1L SMARCC1 ELF1 DNMT3B	1.44e-04	194	61	4	5049f4f102844d766eca577e809cf21f7908a9d2
ToppCell	356C-Endothelial_cells-Endothelial-F_(Lymphatics)-\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	GLT8D2 ITGA9 PROX1 WDTC1	1.50e-04	196	61	4	b04ca69b0ed44e09c989b575f747e1e819cd8008
ToppCell	356C-Endothelial_cells-Endothelial-F_(Lymphatics)\|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)	GLT8D2 ITGA9 PROX1 WDTC1	1.50e-04	196	61	4	a31e227de2dc077b81881295b012d22fedbd65ed
ToppCell	distal-Endothelial-Lymphatic-1\|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	GLT8D2 ITGA9 CHST8 PROX1	1.50e-04	196	61	4	b0f23dc802a2c2a56a08d398a464ea78b58ade4c
ToppCell	distal-1-Endothelial-Lymphatic\|1 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed)	GLT8D2 ITGA9 CHST8 PROX1	1.56e-04	198	61	4	b6fea363463c8dd7e6780c085ece4900266a6286
ToppCell	Neuronal-Inhibitory-iA-iA_3(VIP)-VIP_3-HS3ST3A1\|Neuronal / cells hierarchy compared to all cells using T-Statistic	EGFR TTC38 PREX2 PROX1	1.62e-04	200	61	4	dd68ce6934eafb75d918042fcf7fd7a750294b7f
ToppCell	Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-NMBR\|Neuronal / cells hierarchy compared to all cells using T-Statistic	EGFR RIMBP2 PREX2 PROX1	1.62e-04	200	61	4	862db57d043bdf3cb059fbfc8b29bc1eafdf64ec
ToppCell	Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-NMBR--L1\|Neuronal / cells hierarchy compared to all cells using T-Statistic	EGFR RIMBP2 PREX2 PROX1	1.62e-04	200	61	4	a91345f268f13170c27309333603eb82400c9947
ToppCell	Neuronal-Inhibitory-iA-iA_1(SST_PAX6)-NMBR-\|Neuronal / cells hierarchy compared to all cells using T-Statistic	EGFR RIMBP2 PREX2 PROX1	1.62e-04	200	61	4	d416a7be1a4e6232fb58a9687774da24821f1fdd
ToppCell	Neuronal-Inhibitory-iA-iA_3(VIP)-VIP_3-HS3ST3A1-L3-6\|Neuronal / cells hierarchy compared to all cells using T-Statistic	EGFR TTC38 PREX2 PROX1	1.62e-04	200	61	4	06ea96428728199a30a0f836647d6448287d3848
Drug	5-bromo-2-pyrimidinone	APOBEC3G APOBEC3F	6.60e-06	2	59	2	CID000101494
Drug	Hesperetin [520-33-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A	EPPK1 MEGF9 RABGAP1L FBXO11 ELF4 EXOC7	1.16e-05	196	59	6	1531_DN
Drug	Phenformin hydrochloride [834-28-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A	DNAJB12 KIDINS220 ELF4 EXOC7 CHST8 WDTC1	1.16e-05	196	59	6	4747_DN
Drug	Astemizole [68844-77-9]; Down 200; 8.8uM; MCF7; HT_HG-U133A	DNAJB12 KIDINS220 EGFR EXOC7 TTC38 WDTC1	1.23e-05	198	59	6	2211_DN
Drug	N-isopropylammelide	APOBEC3G APOBEC3F	1.98e-05	3	59	2	CID000441083
Drug	5-fluorocytidine	APOBEC3G DNMT3B APOBEC3F	3.65e-05	25	59	3	CID000016861
Drug	IAPE	APOBEC3G APOBEC3F	3.95e-05	4	59	2	CID000131739
Drug	Cytosar-U	ERF EGFR APOBEC3G IFNE ITPR1 DNMT3B APOBEC3F	7.50e-05	399	59	7	CID000000596
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	EPPK1 NRXN3 KIDINS220 MEGF9 DNMT3B	8.59e-05	173	59	5	7285_UP
Drug	Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; PC3; HT_HG-U133A	SPTLC3 EPPK1 NRXN3 ITPR1 DNMT3B	8.59e-05	173	59	5	2105_UP
Drug	4-imidazolone-5-propionic acid	APOBEC3G APOBEC3F	9.84e-05	6	59	2	CID000000128
Drug	trichostatin A, Streptomyces sp.; Down 200; 1uM; PC3; HT_HG-U133A	DNAJB12 RBM4B APOBEC3G ELF1 ELF4	1.21e-04	186	59	5	6874_DN
Drug	Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A	RBM4 SMARCC1 FBXO11 ELF1 TTC38	1.30e-04	189	59	5	4304_DN
Drug	phenylacetaldehyde	UBE3A APOBEC3G SPAG17 APOBEC3F	1.32e-04	100	59	4	CID000000998
Drug	Nocodazole [31430-18-9]; Down 200; 13.2uM; PC3; HT_HG-U133A	DNAJB12 EGFR RBM4B AKAP8L ITPR1	1.33e-04	190	59	5	7145_DN
Drug	Smoke	DOCK2 PTK2B EPPK1 EGFR RBM4 ELF1 ERMP1 TTC38 CHST8 PROX1	1.33e-04	937	59	10	ctd:D012906
Drug	formylglutamate	APOBEC3G APOBEC3F	1.37e-04	7	59	2	CID000102672
Drug	Imipenem [74431-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A	DNAJB12 UBE3A RBM4 ITPR1 WDTC1	1.40e-04	192	59	5	2873_DN
Drug	Carbarsone [121-59-5]; Down 200; 15.4uM; MCF7; HT_HG-U133A	RABGAP1L FBXO11 EXOC7 ITPR1 WDTC1	1.40e-04	192	59	5	4110_DN
Drug	GSK-3 Inhibitor IX; Down 200; 0.5uM; PC3; HT_HG-U133A	ERF RBM4 SMARCC2 EXOC7 ITPR1	1.40e-04	192	59	5	7106_DN
Drug	FIGLU	APOBEC3G PDXK APOBEC3F	1.41e-04	39	59	3	CID000000909
Drug	semustine; Down 200; 100uM; PC3; HT_HG-U133A	EPPK1 APOBEC3G ELF4 ERMP1 ITPR1	1.47e-04	194	59	5	7545_DN
Drug	Harmol hydrochloride monohydrate [40580-83-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A	RBM4B RABGAP1L FBXO11 ELF4 WDTC1	1.47e-04	194	59	5	2900_DN
Drug	radicicol; Down 200; 0.1uM; PC3; HT_HG-U133A	SPTLC3 KIDINS220 EGFR RABGAP1L WDTC1	1.47e-04	194	59	5	5952_DN
Drug	Bumetanide [28395-03-1]; Down 200; 11uM; HL60; HT_HG-U133A	DNAJB12 ASB7 TTC38 PREX2 WDTC1	1.51e-04	195	59	5	2409_DN
Drug	Chlorambucil [305-03-3]; Down 200; 13.2uM; MCF7; HT_HG-U133A	PTK2B RABGAP1L EXOC7 CHST8 ITPR1	1.51e-04	195	59	5	4345_DN
Drug	0173570-0000 [211245-44-2]; Down 200; 10uM; MCF7; HT_HG-U133A	DNAJB12 SPTLC3 MEGF9 RBM4B FBXO11	1.51e-04	195	59	5	4712_DN
Drug	Tomatidine [77-59-8]; Down 200; 9.6uM; HL60; HG-U133A	PTK2B UBE3A STAU2 SMARCC2 ELF4	1.51e-04	195	59	5	1754_DN
Drug	Cefepime hydrochloride [123171-59-5]; Down 200; 7.4uM; HL60; HT_HG-U133A	KIDINS220 MEGF9 SMARCC1 FBXO11 ELF1	1.51e-04	195	59	5	6159_DN
Drug	AH23848 hemicalcium salt hydrate; Down 200; 1uM; MCF7; HT_HG-U133A	DNAJB12 EGFR RABGAP1L UGGT2 TTC38	1.51e-04	195	59	5	6890_DN
Drug	Prazosin hydrochloride [19237-84-4]; Down 200; 9.6uM; PC3; HT_HG-U133A	EGFR APOBEC3G ERMP1 DARS2 WDTC1	1.54e-04	196	59	5	6315_DN
Drug	Brompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A	KIDINS220 MEGF9 EGFR EXOC7 WDTC1	1.54e-04	196	59	5	3271_DN
Drug	Hydrastinine hydrochloride [4884-68-8]; Down 200; 16.4uM; PC3; HT_HG-U133A	KIDINS220 ERF ELF4 EXOC7 ITPR1	1.54e-04	196	59	5	2119_DN
Drug	Amikacin hydrate [37517-28-5]; Up 200; 6.6uM; PC3; HT_HG-U133A	DNAJB12 NRXN3 KIDINS220 RIMBP2 PROX1	1.54e-04	196	59	5	6715_UP
Drug	Mefenamic acid [61-68-7]; Down 200; 16.6uM; PC3; HT_HG-U133A	EPPK1 SMARCC2 EXOC7 AKAP8L ITPR1	1.54e-04	196	59	5	1821_DN
Drug	clozapine; Down 200; 10uM; PC3; HT_HG-U133A	KIDINS220 ERF EGFR FBXO11 EXOC7	1.54e-04	196	59	5	4453_DN
Drug	Benzamil hydrochloride [2898-76-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A	DNAJB12 KIDINS220 MEGF9 RABGAP1L CHST8	1.54e-04	196	59	5	4760_DN
Drug	beta- Belladonnine dichloroethylate [191355-47-2]; Down 200; 6uM; MCF7; HT_HG-U133A	DNAJB12 SMARCC1 ELF4 PREX2 ITPR1	1.54e-04	196	59	5	4984_DN
Drug	Austricine [10180-88-8]; Down 200; 14.2uM; MCF7; HT_HG-U133A	DNAJB12 KIDINS220 UBE3A ELF1 AKAP8L	1.58e-04	197	59	5	2812_DN
Drug	Domperidone maleate; Down 200; 7.4uM; PC3; HT_HG-U133A	SPTLC3 MEGF9 RABGAP1L RIMBP2 TTC38	1.58e-04	197	59	5	4640_DN
Drug	Liothyronine [6893-02-3]; Down 200; 6.2uM; HL60; HT_HG-U133A	DNAJB12 PTK2B RBM4 EXOC7 TTC38	1.58e-04	197	59	5	2984_DN
Drug	Trimethoprim [738-70-5]; Down 200; 13.8uM; MCF7; HT_HG-U133A	DNAJB12 EPPK1 EXOC7 TTC38 ITPR1	1.58e-04	197	59	5	2307_DN
Drug	Berberine chloride [633-65-8]; Up 200; 10.8uM; PC3; HT_HG-U133A	MEGF9 EGFR RABGAP1L CNOT1 TTC38	1.58e-04	197	59	5	7143_UP
Drug	Ofloxacin [82419-36-1]; Down 200; 11uM; PC3; HT_HG-U133A	EGFR ASB7 SMARCC2 EXOC7 TTC38	1.62e-04	198	59	5	7372_DN
Drug	5211181; Down 200; 12uM; MCF7; HT_HG-U133A_EA	EPPK1 RBM4 FBXO11 ELF4 TTC38	1.62e-04	198	59	5	950_DN
Drug	carbamazepine; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA	DNAJB12 RABGAP1L ELF1 UGGT2 AKAP8L	1.62e-04	198	59	5	919_DN
Drug	Gliquidone [33342-05-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A	KIDINS220 EGFR RABGAP1L SMARCC1 EXOC7	1.62e-04	198	59	5	6505_DN
Drug	Benzamil hydrochloride [2898-76-2]; Down 200; 11.2uM; PC3; HT_HG-U133A	DNAJB12 ERF MEGF9 ELF4 CHST8	1.62e-04	198	59	5	3738_DN
Drug	Mebendazole [31431-39-7]; Down 200; 13.6uM; MCF7; HT_HG-U133A	MEGF9 RBM4B RABGAP1L FBXO11 TTC38	1.62e-04	198	59	5	4694_DN
Drug	Dioxybenzone [131-53-3]; Down 200; 16.4uM; MCF7; HT_HG-U133A	SPTLC3 EGFR SMARCC2 EXOC7 TTC38	1.62e-04	198	59	5	5699_DN
Drug	Dibucaine [85-79-0]; Down 200; 11.6uM; HL60; HG-U133A	STAU2 SMARCC2 UGGT2 ELF4 ITPR1	1.62e-04	198	59	5	1969_DN
Drug	Oxytetracycline dihydrate [6153-64-6]; Up 200; 8uM; MCF7; HT_HG-U133A	DNAJB12 RIMBP2 ITGA9 EXOC7 ITPR1	1.62e-04	198	59	5	3170_UP
Drug	cyclosporine A; Down 200; 1uM; MCF7; HG-U133A	KIDINS220 ERF MEGF9 EXOC7 WDTC1	1.62e-04	198	59	5	602_DN
Drug	Nisoxetine hydrochloride [57754-86-6]; Down 200; 13uM; HL60; HT_HG-U133A	DNAJB12 PTK2B APOBEC3G ELF4 EXOC7	1.62e-04	198	59	5	3117_DN
Drug	Chlorambucil [305-03-3]; Down 200; 13.2uM; MCF7; HT_HG-U133A	RABGAP1L EXOC7 TTC38 CHST8 WDTC1	1.62e-04	198	59	5	3869_DN
Drug	Tolazamide [1156-19-0]; Down 200; 12.8uM; MCF7; HT_HG-U133A	EGFR FBXO11 ELF4 TTC38 WDTC1	1.62e-04	198	59	5	2842_DN
Drug	Ethaverine hydrochloride [985-13-7]; Up 200; 9.2uM; MCF7; HT_HG-U133A	SMARCC2 ELF4 EXOC7 TTC38 ITPR1	1.66e-04	199	59	5	5337_UP
Drug	Dapsone [80-08-0]; Down 200; 16.2uM; MCF7; HT_HG-U133A	SPTLC3 RABGAP1L UGGT2 ELF4 AKAP8L	1.66e-04	199	59	5	5498_DN
Drug	Proparacaine hydrochloride [5875-06-9]; Down 200; 12uM; MCF7; HT_HG-U133A	DNAJB12 KIDINS220 ELF4 EXOC7 CHST8	1.66e-04	199	59	5	6492_DN
Drug	Tropine [120-29-6]; Up 200; 28.4uM; MCF7; HT_HG-U133A	RABGAP1L FBXO11 AKAP8L CHST8 WDTC1	1.66e-04	199	59	5	3569_UP
Drug	2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; PC3; HT_HG-U133A	MEGF9 EGFR APOBEC3G SMARCC2 WDTC1	1.66e-04	199	59	5	6321_DN
Drug	Cyclopentolate hydrochloride [5870-29-1]; Down 200; 12.2uM; HL60; HT_HG-U133A	DNAJB12 KIDINS220 RABGAP1L ELF4 WDTC1	1.66e-04	199	59	5	6132_DN
Drug	Merbromin [129-16-8]; Down 200; 5uM; PC3; HT_HG-U133A	SPTLC3 EGFR SMARCC1 EXOC7 ITPR1	1.66e-04	199	59	5	7398_DN
Drug	AG-013608 [351320-38-2]; Down 200; 10uM; PC3; HT_HG-U133A	DNAJB12 KIDINS220 RABGAP1L TTC38 PDXK	1.66e-04	199	59	5	5949_DN
Drug	Carbinoxamine maleate salt [3505-38-2]; Down 200; 9.8uM; HL60; HT_HG-U133A	DNAJB12 SPTLC3 RABGAP1L EXOC7 DNMT3B	1.66e-04	199	59	5	2725_DN
Drug	Diprophylline [479-18-5]; Up 200; 15.8uM; PC3; HT_HG-U133A	KIDINS220 RABGAP1L DARS2 PDXK CHST8	1.66e-04	199	59	5	1811_UP
Drug	Oleandomycin phosphate [7060-74-4]; Down 200; 5uM; PC3; HG-U133A	STAU2 SMARCC1 SMARCC2 CNOT1 PDXK	1.66e-04	199	59	5	1935_DN
Drug	Finasteride [98319-26-7]; Down 200; 10.8uM; PC3; HT_HG-U133A	DNAJB12 APOBEC3G FBXO11 PREX2 CHST8	1.66e-04	199	59	5	3744_DN
Drug	Harpagoside [19210-12-9]; Up 200; 8uM; MCF7; HT_HG-U133A	RABGAP1L SMARCC2 TTC38 AKAP8L ITPR1	1.66e-04	199	59	5	7355_UP
Drug	Trimethylcolchicinic acid [3482-37-9]; Up 200; 11.6uM; PC3; HT_HG-U133A	DNAJB12 APOBEC3G TDO2 PREX2 ITPR1	1.69e-04	200	59	5	4202_UP
Drug	Isoxicam [34552-84-6]; Down 200; 12uM; PC3; HT_HG-U133A	ASB7 SMARCC2 ELF4 ERMP1 WDTC1	1.69e-04	200	59	5	7268_DN
Drug	NSC123799	APOBEC3G APOBEC3F	1.83e-04	8	59	2	CID000270928
Drug	FP-21399	APOBEC3G APOBEC3F	1.83e-04	8	59	2	CID006510265
Drug	C0761	APOBEC3G APOBEC3F	1.83e-04	8	59	2	CID006321196
Drug	N-cyclopropylammelide	APOBEC3G APOBEC3F	1.83e-04	8	59	2	CID000592814
Drug	Ag43	PTK2B EGFR	1.83e-04	8	59	2	CID000005613
Drug	Potassium Chloride	PTK2B NRXN3 NRXN2 ITPR1	2.42e-04	117	59	4	ctd:D011189
Drug	BPIQ-I	PTK2B EGFR	2.93e-04	10	59	2	CID000002427
Disease	DNA dC->dU-editing enzyme APOBEC-3G measurement	APOBEC3G APOBEC3F	1.14e-05	3	58	2	EFO_0802473
Disease	Autism Spectrum Disorders	NRXN3 NRXN2 FEV DNMT3B	2.42e-05	85	58	4	C1510586
Disease	opportunistic bacterial infectious disease (implicated_via_orthology)	SMARCC1 SMARCC2	1.35e-04	9	58	2	DOID:0050340 (implicated_via_orthology)
Disease	Coffin-Siris syndrome (implicated_via_orthology)	SMARCC1 SMARCC2	1.35e-04	9	58	2	DOID:1925 (implicated_via_orthology)
Disease	pneumococcal bacteremia	DOCK2 DOCK7	2.06e-04	11	58	2	EFO_1001925
Disease	Craniofacial Abnormalities	ERF EGFR UBE3A DNMT3B	2.55e-04	156	58	4	C0376634
Disease	word reading	MMS22L NRXN3 DOCK7	2.89e-04	65	58	3	EFO_0005300
Disease	hepatocellular carcinoma (is_marker_for)	EGFR SMARCC1 FBXO11 PREX2 DNMT3B	3.15e-04	301	58	5	DOID:684 (is_marker_for)
Disease	breast carcinoma (is_implicated_in)	EGFR FBXO11	1.11e-03	25	58	2	DOID:3459 (is_implicated_in)
Disease	urate measurement, bone density	SPTLC3 KIDINS220 RABGAP1L UGGT2 TDO2 ITPR1	1.33e-03	619	58	6	EFO_0003923, EFO_0004531
Disease	Autistic Disorder	NRXN3 NRXN2 UBE3A TDO2	1.74e-03	261	58	4	C0004352
Disease	forced expiratory volume, response to bronchodilator	MMS22L EPPK1 NRXN2 SPAG17 KLHL32	1.81e-03	445	58	5	EFO_0004314, GO_0097366
Disease	Chloracne	EPPK1 EGFR	1.93e-03	33	58	2	C0263454

Protein segments in the cluster

Peptide	Gene	Start	Entry
MNYDKLSRALRYYYN	ERFL	91	A0A1W2PQ73
MNYDKLSRALRYYYN	ERF	76	P50548
LDAQRLHYYRGNYMT	ABCF1	521	Q8NE71
YETMGRALRYYYQRG	ELF1	261	P32519
RMLYNYGADTNTRNY	ASB7	231	Q9H672
RFLELFYMYDDDGYQ	DNMT3B	461	Q9UBC3
RMYRDTFSYNFYNRP	APOBEC3G	11	Q9HC16
MNYDKLSRALRYYYD	FEV	96	Q99581
QRYFLADNFMIYLYN	ADAM32	66	Q8TC27
KRFYYMNASAQYLGE	ERMP1	511	Q7Z2K6
AYEGQYDAYRDQFRM	AKAP8L	156	Q9ULX6
GFYLYRMNKYHDDQR	CAPN14	421	A8MX76
RNSLYDMARYEREQY	RBM4	341	Q9BWF3
MFLQYYLNEQGDRVY	NOP10	1	Q9NPE3
AEYRDAYREYIAQMS	KIDINS220	1381	Q9ULH0
LSYYRYQLNLFARMC	ITPR1	731	Q14643
NYETMGRALRYYYQR	ELF4	261	Q99607
RQFIQDYGMRYYYQV	MMS22L	1161	Q6ZRQ5
LDYNLQRDYYGGMYS	HNRNPCL3	111	B7ZW38
LYAMYKYRNRDEGSY	NRXN3	1586	Q9Y4C0
FVGAVYMYREYQNRK	MEGF9	531	Q9H1U4
LVGLQNTYMGYLDYR	GLT8D2	196	Q9H1C3
LDYNLQRDYYGGMYS	HNRNPCL4	111	P0DMR1
RNSLYDMARYEREQY	RBM4B	336	Q9BQ04
RRGMYRYNALYSLDG	EXOC8	221	Q8IYI6
LVEYGRNQDFMNVYY	EXOC7	206	Q9UPT5
IMYDYGLRDLYRNNF	RABGAP1L	646	Q5R372
ILLYAMYKYRNRDEG	NRXN2	606	P58401
DEVIMNRRYTYLGYA	ITGA9	236	Q13797
IIRGNMYYENSYALA	EGFR	106	P00533
DLDFARQYYEMLYNT	EXOC4	891	Q96A65
RMYRDTFSYNFYNRP	APOBEC3F	11	Q8IUX4
YKDNNREEMYIRYLY	DOCK2	1211	Q92608
YFDKNYNLRRFMYCT	DOCK7	1931	Q96N67
NPARYKGRENMLYYD	FBXO11	256	Q86XK2
YRARYFGDTDMYHRA	DNAJB12	341	Q9NXW2
YETMGRALRYYYQRG	ELF2	261	Q15723
LLYFYQQLRNDYMQR	PTK2B	151	Q14289
MYFRRIHDYLENQDY	IFNE	146	Q86WN2
RYKYQFFNLRPNMAY	RIMBP2	436	O15034
LQYRYLDLRSFQMQY	DARS2	171	Q6PI48
YRALQGALMIYFYRE	TDO2	286	P48775
NFREFYYIQMEKYAR	PROX1	626	Q92786
DVAYRRGYFDQMLNL	EPPK1	741	P58107
YLYNLGDQYALKMRF	RPN1	341	P04843
ENFFAMLRGYRVENY	SIPA1L2	206	Q9P2F8
LYQDFENFYTRNLYM	SPTLC3	106	Q9NUV7
IYLAYRNFMIDTYRL	SMARCC1	486	Q92922
IYLAYRNFMIDTYRL	SMARCC2	461	Q8TAQ2
YEGLRLNNMNKYDYV	PDXK	66	O00764
MRYYNYLLNPIREEF	SPAG17	426	Q6Q759
SALQRQRTYDFYYMD	CHST8	396	Q9H2A9
MLRNLFEEYRFFPQY	CNOT1	891	A5YKK6
EMVLRERSYDYQFRY	WDTC1	516	Q8N5D0
LGLYYDNRIRMYSER	UBE3A	491	Q05086
FPNYRANYNFRGMYN	STAU2	121	Q9NUL3
ATYREGFYNEYMQRV	PHOSPHO1	61	Q8TCT1
EQMLYRFRYDDGTFY	PREX2	456	Q70Z35
AYFYLGYQEQMRDSV	TTC38	151	Q5R3I4
SDYYDLGYNMRSNLF	TEX33	196	O43247
MAKEYGFRYELVQYR	UGGT2	1281	Q9NYU1
YQYMDELLQYIRFGL	KLHL32	221	Q96NJ5